Genetically engineered CSPG4-targeted CAR T cells have been shown to control tumor growth cells in vitro and in vivo in with different cell lines engrafted NSG mice (human melanoma, head and neck squamous cell carcinoma and breast carcinoma) and has been able to kill CSPG4 expressing glioblastoma cancer stem cells (42, 43). This evidence concerns the gene CSPG4 and glioblastoma.